The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recently extended its support for three innovative therapies aimed at treating autoimmune disorders, muscle wasting, and rare genetic diseases. This positive feedback marks a significant step forward for the pharmaceutical landscape in Europe.
Sanofi’s Breakthrough in Multiple Sclerosis
Sanofi has received a favorable opinion from the CHMP for its therapy targeting non-relapsing secondary progressive multiple sclerosis (nrSPMS), known as Cenrifki (tolebrutinib). This approval comes despite a setback in the United States, where regulatory bodies had reservations regarding the drug’s potential to cause liver injuries.
Cenrifki, a Bruton’s tyrosine kinase (BTK) inhibitor, garnered the CHMP’s endorsement due to promising data from the Phase III HERCULES trial. The results demonstrated that Cenrifki effectively extended the time before confirmed disability progression occurred, showing a 31% improvement compared to placebo. Now, the European Medicines Agency will deliberate on granting official approval, which Sanofi anticipates will happen in the near future.
This development is particularly noteworthy considering ongoing safety concerns surrounding Roche’s MS candidate, fenebrutinib, another BTK inhibitor under evaluation. Experts in multiple sclerosis have noted the considerable potential for BTK inhibitors in treating this condition, while emphasizing the importance of monitoring liver enzyme levels in patients.
Arrowhead’s Ambitious Plans for Rare Disease Therapy
Arrowhead Pharmaceuticals is also making strides with its rare disease therapy, Redemplo (plozasiran). While the drug has been available in the U.S. for patients with familial chylomicronemia syndrome (FCS), it has yet to penetrate the European market.
Arrowhead is optimistic about Redemplo’s future, with the EMA expected to make a decision about its market approval based on the results from the Phase III PALISADE study. This trial reported an impressive median reduction of 80% in patient triglyceride levels, leading to significantly fewer acute pancreatitis incidents when compared to placebo.
If approved, Redemplo will be the first small interfering RNA (siRNA) therapy targeting FCS, challenging the current European market dominance of Ionis’ therapies, Tryngolza and Waylivra. Analysts predict that Redemplo could generate up to $1 billion in sales by 2032, surpassing its competitors.
Novartis Enters the Spinal Muscular Atrophy Market
The third therapy to receive a nod from the CHMP is Novartis’ Itvisma (onasemnogene abeparvovec), aimed at treating spinal muscular atrophy (SMA). This therapy made its debut in the U.S. market in November 2025, and the CHMP’s positive opinion is based on favorable outcomes from the Phase III STEER study.
The STEER study demonstrated that Itvisma could significantly enhance motor function over a 52-week period. Novartis touts this one-time gene-targeting replacement therapy as a potential way to reduce the ongoing need for chronic SMA treatments, thereby alleviating the overall disease burden for patients aged two and older.
If granted approval, Itvisma would enhance Novartis’ foothold in the SMA market, which is currently dominated by its existing gene therapy, Zolgensma (onasemnogene abeparvovec). It would also represent the first gene replacement therapy to receive European regulatory approval for SMA, providing new alternatives to currently available treatments like Roche’s Evrysdi (risdiplam) and Biogen’s Spinraza (nusinersen).
The Competitive Landscape
As Novartis seeks to expand its presence, Roche continues to lead the SMA market with Evrysdi, which was recognized as the best-selling drug in this category in 2025. Evrysdi’s unique formulation, available in both liquid and pill forms, marked it as the first non-invasive treatment for SMA approved in Europe.
Conclusion
The recent endorsements from the CHMP for these three therapies underline the dynamic nature of the European pharmaceutical market. With significant potential for improving patient outcomes across diverse conditions, these approvals may reshape treatment paradigms and create new opportunities for both healthcare providers and patients. The coming months will be pivotal as the EMA finalizes its decisions on these promising therapies.
- Takeaways:
- Sanofi’s Cenrifki shows promise for multiple sclerosis despite U.S. regulatory hurdles.
- Arrowhead’s Redemplo could lead the siRNA therapy market for FCS if approved in Europe.
- Novartis’ Itvisma aims to transform spinal muscular atrophy treatment options.
- The competitive landscape is heating up, with established players closely watched by emerging therapies.
Read more → www.pharmaceutical-technology.com